Another disappointing quarter from Gilead, shares down almost 6%

Gilead has posted another disappointing quarter and its shares have reacted by dropping 5.8% in after-hours trading.  The cause for the decline has been the same for two years now–sales of hepatitis C drugs keep dropping, since the disease is less and less widespread and competitors–especially AbbVie–are growing stronger and stronger.